Carfilzomib-dexamethasone vs bortezomib-dexamethasone in
relapsed or refractory multiple myeloma by cytogenetic risk in
the phase 3 study ENDEAVOR

J 2017

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

CHNG, W.J., H. GOLDSCHMIDT, M.A. DIMOPOULOS, P. MOREAU, D. JOSHUA et. al.

Základní údaje

Originální název

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2017, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.023

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/leu.2016.390

UT WoS

000402832700015

Klíčová slova anglicky

LOW-DOSE DEXAMETHASONE; STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; INTERGROUPE FRANCOPHONE; DELETION 17P; LENALIDOMIDE; THERAPY; ABNORMALITIES; POMALIDOMIDE; THALIDOMIDE

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 3. 2018 15:01, Soňa Böhmová

Anotace

V originále

The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 [25%]; Vd, n=113 [28%]) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 [75%]; Vd, n=291 [72%]). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.45–0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33–0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved greater than or equal toCR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.

Citovat

CHNG, W.J., H. GOLDSCHMIDT, M.A. DIMOPOULOS, P. MOREAU, D. JOSHUA, A. PALUMBO, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. FENG, S. AGGARWAL a R. HÁJEK. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. London: Nature Publishing Group, 2017, roč. 31, č. 6, s. 1368-1374. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2016.390.

@article{1368645,
   author = {Chng, W.J. and Goldschmidt, H. and Dimopoulos, M.A. and Moreau, P. and Joshua, D. and Palumbo, A. and Facon, T. and Ludwig, H. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosiñol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Gillenwater, H.H. and Mohamed, N. and Feng, S. and Aggarwal, S. and Hájek, R.},
   article_location = {London},
   article_number = {6},
   doi = {http://dx.doi.org/10.1038/leu.2016.390},
   keywords = {LOW-DOSE DEXAMETHASONE; STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; INTERGROUPE FRANCOPHONE; DELETION 17P; LENALIDOMIDE; THERAPY; ABNORMALITIES; POMALIDOMIDE; THALIDOMIDE},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR},
   url = {http://dx.doi.org/10.1038/leu.2016.390},
   volume = {31},
   year = {2017}
}

TY  - JOUR
ID  - 1368645
AU  - Chng, W.J. - Goldschmidt, H. - Dimopoulos, M.A. - Moreau, P. - Joshua, D. - Palumbo, A. - Facon, T. - Ludwig, H. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosiñol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Gillenwater, H.H. - Mohamed, N. - Feng, S. - Aggarwal, S. - Hájek, R.
PY  - 2017
TI  - Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
JF  - Leukemia
VL  - 31
IS  - 6
SP  - 1368-1374
EP  - 1368-1374
PB  - Nature Publishing Group
SN  - 08876924
KW  - LOW-DOSE DEXAMETHASONE
KW  - STEM-CELL TRANSPLANTATION
KW  - PLUS DEXAMETHASONE
KW  - INTERGROUPE FRANCOPHONE
KW  - DELETION 17P
KW  - LENALIDOMIDE
KW  - THERAPY
KW  - ABNORMALITIES
KW  - POMALIDOMIDE
KW  - THALIDOMIDE
UR  - http://dx.doi.org/10.1038/leu.2016.390
L2  - http://dx.doi.org/10.1038/leu.2016.390
N2  - The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (MM). We conducted a preplanned subgroup analysis of ENDEAVOR to evaluate Kd vs Vd by cytogenetic risk. Of 785 patients with known cytogenetics, 210 (27%) had high-risk cytogenetics (Kd, n=97 [25%]; Vd, n=113 [28%]) and 575 (73%) had standard-risk cytogenetics (Kd, n=284 [75%]; Vd, n=291 [72%]). Median PFS in the high-risk group was 8.8 months for Kd vs 6.0 months for Vd (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.45–0.92; P=0.0075). Median PFS in the standard-risk group was not estimable for Kd vs 10.2 months for Vd (HR, 0.44; 95% CI, 0.33–0.58; P<0.0001). Overall response rates were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved greater than or equal toCR. This preplanned subgroup analysis found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.
ER  -

CHNG, W.J., H. GOLDSCHMIDT, M.A. DIMOPOULOS, P. MOREAU, D. JOSHUA, A. PALUMBO, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. FENG, S. AGGARWAL a R. HÁJEK. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. \textit{Leukemia}. London: Nature Publishing Group, 2017, roč.~31, č.~6, s.~1368-1374. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2016.390.

Podrobný výpis o publikaci